SMA Medicine Controversy in Kerala Assembly Over Labels
Kerala's Chief Minister V.D. Satheesan has stood firmly behind the state government's move to provide an affordable Indian-manufactured drug to children with spinal muscular atrophy (SMA). On Monday, he dismissed opposition criticism and lauded the work of the state health department.
In the Assembly, Satheesan questioned the opposition's stance, asking what was wrong with selling medicines to poor children at a lower price. He asked whether the real concern of the opposition was the large drop in the cost of treatment.
According to the Chief Minister, a 12-day course of the drug, once priced at around Rs 65 lakh, is now available for Rs 15,000. He extended his congratulations to Health Minister K. Muraleedharan and the department for securing such a substantial reduction.
The issue gained political heat after packets of the generic drug given to children at SAT Hospital in Thiruvananthapuram were found to bear the labels 'Physician's Sample' and 'Only for Clinical Trials.' Parents have expressed concern that their children may have been given medicines meant for trials.
Three former health ministers from the CPI(M), who are part of the opposition, have raised doubts about the drug's safety and the procurement methods used. The government, however, maintains that the medicine, produced by Hyderabad-based Natco Pharma and sold under the NatSmart brand, has backing from experts and regulatory clearance. The health department has explained that the labels appeared on sample stock supplied during a temporary shortage.
Muraleedharan informed the Assembly that Rs 50 crore remains unpaid for medicines bought during the tenure of the previous Pinarayi Vijayan government. He assured that the low-cost supply of the SMA drug would continue and said affordable care would help more children get the treatment they need.
He also made a pointed remark at his critics, saying that since becoming a minister, he had not formed the habit of appointing his daughter-in-law as a cook.
The opposition continues to seek clarity on the labelled medicine, while the government insists that the affordable generic supply will not be disrupted. SMA is a rare inherited disorder that slowly weakens muscles, and high treatment costs make cheaper medicines a vital concern for families.